Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Mazen K Ali & Raymond W Lam. (2011) Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 7, pages 39-49.
Read now
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now
Read now
Christophe Lançon, Patrice Verpillat, Lieven Annemans, Nicolas Despiegel & Clément François. (2007) Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. International Journal of Psychiatry in Clinical Practice 11:1, pages 44-52.
Read now
Read now
J.-P. Boulenger, A. K. T. Huusom, I. Florea, T. Bækdal & M. Sarchiapone. (2006) A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Current Medical Research and Opinion 22:7, pages 1331-1341.
Read now
Read now
Michael E Thase. (2006) Managing depressive and anxiety disorders with escitalopram. Expert Opinion on Pharmacotherapy 7:4, pages 429-440.
Read now
Read now
Thomas C. Baghai, Hans-Peter Volz & Hans-Jürgen Möller. (2006) Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. The World Journal of Biological Psychiatry 7:4, pages 198-222.
Read now
Read now
Christophe Lançon, Christophe Sapin, Ivan Note & Jean Farisse. (2006) Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study. International Journal of Psychiatry in Clinical Practice 10:2, pages 131-137.
Read now
Read now
David S. Baldwin. (2006) The importance of long-term tolerability in achieving recovery. International Journal of Psychiatry in Clinical Practice 10:sup1, pages 31-37.
Read now
Read now
Dan J. Stein. (2006) Evidence-based treatment of anxiety disorders. International Journal of Psychiatry in Clinical Practice 10:sup1, pages 16-21.
Read now
Read now
Lucien Colonna, Henning Friis Andersen & Elin Heldbo Reines. (2005) A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Current Medical Research and Opinion 21:10, pages 1659-1668.
Read now
Read now
Siegfried Kasper. (2004) Unique mechanism of action for escitalopram: does it hold the promise?. International Journal of Psychiatry in Clinical Practice 8:sup1, pages 15-18.
Read now
Read now
Articles from other publishers (36)
Vinod Kumar Vashistha, Sonika Sethi, Inderjeet Tyagi & Dipak Kumar Das. (2022) Chirality of antidepressive drugs: an overview of stereoselectivity. Asian Biomedicine 16:2, pages 55-69.
Crossref
Crossref
Gerd Laux. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1257
1269
.
Satish S.C. Rao, Enrique Coss-Adame, Yun Yan, Askin Erdogan, Jessica Valestin & Deepak Nag Ayyala. (2021) Sensory Adaptation Training or Escitalopram for IBS With Constipation and Rectal Hypersensitivity: A Randomized Controlled Trial. Clinical and Translational Gastroenterology 12:7, pages e00381.
Crossref
Crossref
Gerd Laux. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
13
.
Monica Budău, Gabriel Hancu, Aura Rusu, Melania Cârcu-Dobrin & Daniela Lucia Muntean. (2017) Chirality of Modern Antidepressants: An Overview. Advanced Pharmaceutical Bulletin 7:4, pages 495-500.
Crossref
Crossref
Isaac Ng, H. Karl Greenblatt & David J. Greenblatt. (2016) Stereo-Psychopharmacology: The Case of Citalopram and Escitalopram. Clinical Pharmacology in Drug Development 5:5, pages 331-335.
Crossref
Crossref
Himanshu Naik, Serena Chan, Majid Vakilynejad, Grace Chen, Henrik Loft, Atul R. Mahableshwarkar & Johan Areberg. (2015) A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic & Clinical Pharmacology & Toxicology 118:5, pages 344-355.
Crossref
Crossref
Karen E. Murray, Kerry J. Ressler & Michael J. Owens. (2016) In vivo investigation of escitalopram's allosteric site on the serotonin transporter. Pharmacology Biochemistry and Behavior 141, pages 50-57.
Crossref
Crossref
Borwin Bandelow. (2013) In Reply. Deutsches Ärzteblatt international.
Crossref
Crossref
B. R. Rutherford, S. M. Marcus, P. Wang, J. R. Sneed, G. Pelton, D. Devanand, N. Duan & S. P. Roose. (2012) A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychological Medicine 43:5, pages 975-982.
Crossref
Crossref
Stuart Montgomery, Thomas Hansen & Siegfried Kasper. (2010) Efficacy of escitalopram compared to citalopram: a meta-analysis. The International Journal of Neuropsychopharmacology 14:02, pages 261-268.
Crossref
Crossref
Jian-Jun Ou, Guang-Lei Xun, Ren-Rong Wu, Le-Hua Li, Mao-Sheng Fang, Hong-Geng Zhang, Shi-Ping Xie, Jian-Guo Shi, Bo Du, Xue-Qin Yuan & Jing-Ping Zhao. (2010) Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 213:2-3, pages 639-646.
Crossref
Crossref
Stuart A. Montgomery & Hans-Jürgen Möller. (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. International Clinical Psychopharmacology 24:3, pages 111-118.
Crossref
Crossref
Jacob Andersen, Anders S. Kristensen, Benny Bang-Andersen & Kristian Strømgaard. (2009) Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chemical Communications:25, pages 3677.
Crossref
Crossref
Esra Saglam, Lora Esberk Ates, Hakan Kayir, Turgay Celik, Berna Terzioglu & Tayfun Uzbay. (2008) Escitalopram increases cortical nitric oxide synthase (NOS) in rat brain during ethanol withdrawal. Nitric Oxide 19:3, pages 284-288.
Crossref
Crossref
P. Van Dijck. (2007) Escitalopram, un développement clinique complet. L'Encéphale 33, pages 134-139.
Crossref
Crossref
Stuart A. Montgomery, David S. Baldwin, Pierre Blier, Naomi A. Fineberg, Siegfried Kasper, Malcolm Lader, Raymond W. Lam, Jean-Pierre Lépine, Hans-Jürgen Möller, David J. Nutt, Frederic Rouillon, Alan F. Schatzberg & Michael E. Thase. (2007) Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology 22:6, pages 323-329.
Crossref
Crossref
H.-J. Möller & J. Schnitker. (2007) Einsatz einer modifizierten MADRS bei depressiven Patienten in einer prospektiven KohortenstudieProspective study using a modified Montgomery-Asberg Depression Scale. Der Nervenarzt 78:6, pages 685-690.
Crossref
Crossref
Dietmar Winkler, Edda Pjrek, Ulrike Moser & Siegfried Kasper. (2007) Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. Human Psychopharmacology: Clinical and Experimental 22:4, pages 245-251.
Crossref
Crossref
Bruno Fantino, Nicholas Moore, H??l??ne Verdoux & Jean-Paul Auray. (2007) Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. International Clinical Psychopharmacology 22:2, pages 107-115.
Crossref
Crossref
Hamid Sadri & Nicole Mittmann. (2016) A Qualitative Review of Recent Economic Evaluations of Escitalopram. Journal of Pharmacy Technology 23:1, pages 35-40.
Crossref
Crossref
Stuart A. Montgomery & Henning F. Andersen. (2006) Escitalopram versus venlafaxine XR in the treatment of depression. International Clinical Psychopharmacology 21:5, pages 297-309.
Crossref
Crossref
Connie Sanchez. (2006) The Pharmacology of Citalopram Enantiomers: The Antagonism by R-Citalopram on the Effect of S-Citalopram*. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 99:2, pages 91-95.
Crossref
Crossref
Esra Sağlam, Hakan Kayir, Turgay Çelik & Tayfun Uzbay. (2006) Effects of escitalopram on ethanol withdrawal syndrome in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30:6, pages 1027-1032.
Crossref
Crossref
David S. Baldwin, James A. Cooper, Anna K.T. Huusom & Ian Hindmarch. (2006) A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International Clinical Psychopharmacology 21:3, pages 159-169.
Crossref
Crossref
Siegfried Kasper, Christian Spadone, Patrice Verpillat & Jules Angst. (2006) Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. International Clinical Psychopharmacology 21:2, pages 105-110.
Crossref
Crossref
Stuart A. Montgomery. (2006) Why do we need new and better antidepressants?. International Clinical Psychopharmacology 21:Supplement 1, pages S1-S10.
Crossref
Crossref
Liborio Rampello, Alessandro Alvano, Rocco Raffaele, Mariano Malaguarnera & Ignazio Vecchio. (2006) New Possibilities of Treatment for Panic Attacks in Elderly Patients. Journal of Clinical Psychopharmacology 26:1, pages 67-70.
Crossref
Crossref
David Murdoch & Susan J Keam. (2006) Spotlight on Escitalopram in the Management of Major Depressive Disorder1. CNS Drugs 20:2, pages 167-170.
Crossref
Crossref
Dan J. Stein, Elisabeth Wreford Andersen & Malcolm Lader. (2006) Escitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensions. European Neuropsychopharmacology 16:1, pages 33-38.
Crossref
Crossref
&NA;. (2005) Escitalopram is an effective option for managing major depressive disorder in adults. Drugs & Therapy Perspectives 21:12, pages 1-5.
Crossref
Crossref
Nicholas Moore, H??l??ne Verdoux & Bruno Fantino. (2005) Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International Clinical Psychopharmacology 20:3, pages 131-137.
Crossref
Crossref
P-M Llorca, J-M Azorin, N. Despiegel & P. Verpillat. (2005) Efficacy of escitalopram in patients with severe depression: a pooled analysis. International Journal of Clinical Practice 59:3, pages 268-275.
Crossref
Crossref
Thomas R. Einarson. (2004) Evidence based review of escitalopram in treating major depressive disorder in primary care. International Clinical Psychopharmacology 19:5, pages 305-310.
Crossref
Crossref
J.-M. Azorin, P.-M. Llorca, N. Despiegel & P. Verpillat. (2004) Traitement des épisodes dépressifs sévères : escitalopram est plus efficace que citalopram. L'Encéphale 30:2, pages 158-166.
Crossref
Crossref
S.A. Montgomery, A.K.T. Huusom & J. Bothmer. (2004) A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder. Neuropsychobiology 50:1, pages 57-64.
Crossref
Crossref